Teva Pharma Industries Ltd ADR (TEVA)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE
Market Cap: $51.92B
Last updated: Nov 17, 2026 at 11:06 AM ET
Teva Pharma Industries Ltd ADR (TEVA) P/E Ratio & Valuation History
Teva Pharma Industries Ltd ADR (TEVA) trades at 14.4x trailing earnings and 2.9x sales. Its P/E of 14.4x is above its 5-year median of 5.7x. Its forward P/E is 12.6x. The median P/E across 8 similar companies is 19.9x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 14.3% higher over the next year. Its free cash flow yield is 2.5%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 14.4x |
| Forward P/E | 12.6x |
| Price to sales | 2.9x |
| Price to book | 6.3x |
| EV/EBITDA | 31.0x |
| Price to FCF | 40.8x |
| EV/FCF | 51.0x |
| PEG | 0.7 |
| FCF yield | 2.5% |
Historical Medians
Against its 10-year medians, its P/E is 206.4% above 4.7x, its P/S is 262.5% above 0.8x and its P/B is 425.0% above 1.2x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 14.4x | 5.7x | 4.7x |
| P/S | 2.9x | 1.0x | 0.8x |
| P/B | 6.3x | 2.4x | 1.2x |
Valuation History
Over the 10 year ends shown, its P/E ranged from 3.1x in 2021 to 10.8x in 2025. 2025 was the highest of those years.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $31.21 | 10.8x | 2.1x | 4.6x |
| 2024 | $22.04 | 8.9x | 1.5x | 4.6x |
| 2023 | $10.44 | 4.1x | 0.7x | 1.6x |
| 2022 | $9.12 | 3.6x | 0.7x | 1.3x |
| 2021 | $8.01 | 3.1x | 0.6x | 0.9x |
| 2020 | $9.65 | 3.8x | 0.6x | 1.1x |
| 2019 | $9.80 | 4.1x | 0.6x | 0.8x |
| 2018 | $15.42 | 5.3x | 0.8x | 1.1x |
| 2017 | $18.95 | 4.7x | 0.9x | 1.1x |
| 2016 | $36.25 | 7.1x | 1.6x | 1.1x |
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About TEVA
What is TEVA's forward P/E ratio?
Teva Pharma Industries Ltd ADR has a forward P/E ratio of 12.6x.
Is TEVA stock overvalued?
GNG's valuation label for TEVA is Overvalued. Its P/E of 14.4x compares with a median of 19.9x across 8 similar companies.
What is TEVA's price to sales ratio?
Teva Pharma Industries Ltd ADR has a price to sales ratio of 2.9x.
What is Teva Pharma Industries Ltd ADR's average P/E ratio over 5 years?
Teva Pharma Industries Ltd ADR's median P/E over the last 5 years is 5.7x, from 60 month-end values through Oct 2026.
What is TEVA's PEG ratio?
Teva Pharma Industries Ltd ADR has a PEG ratio of 0.7.
TEVA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors